Category Archives: Uncategorized

“Protect” ML29346 (Dr. Feiner’s IST)

Status: Not Enrolling ClinicalTrials.gov Identifier: NCT02302989 Pro-Con: Prospective double-blind randomized study to evaluate Lucentis for prophylaxis against the conversion to neovascular age-related macular degeneration (AMD in high-risk eyes) Condition: AMD in Fellow Eye Study Type: Interventional Duration: 24 months Eligibility: Ages: Child, … Continue reading

Opthea OPT-302-1002

Status: Enrolling ClinicalTrials.gov Identifier: NCT02543229 Opthea OPT-302-1002: A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD) Condition: AMD Study Type: Interventional Duration: 24 weeks Eligibility: Ages: 50 years … Continue reading

Pro-Con (Dr. Heier IST study)

Status: Not Enrolling ClinicalTrials.gov Identifier: NCT02462889 Pro-Con: A Prospective, Single-blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) versus Sham as PROphylaxis against CONversion to Neovascular Age-related Macular Degeneration (AMD) in High-Risk Eyes Condition: AMD Study Type: Interventional Duration: 24 months Eligibility: … Continue reading

Regeneron CAPELLA

Status: Closed ClinicalTrials.gov Identifier: NCT02418754 Regeneron CAPELLA R2176-3AMD-1417: A Phase 2, Double-masked, Randomized, Controlled, Multiple-dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-related Macular Degeneration Condition: Neovascular AMD Study Type: Interventional Duration: 52 weeks Eligibility: Ages: … Continue reading

Genentech CHROMA GX29176

Status: Not Enrolling ClinicalTrials.gov Identifier: NCT02745119 Genentech CHROMA: A Phase III, Multicenter, Randomized, Double-masked, Sham-controlled Study to assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration Condition: Geographic Atrophy secondary to AMD … Continue reading

Aerpio AKB-9778-Cl-5001

Status: Enrolling ClinicalTrials.gov Identifier: NCT03197870 Aerpio: Phase 2 Double-Masked, Placebo-controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15 MG Once Daily or 15 MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative … Continue reading

Alpha Lipoic Acid in Geographic Atrophy (ALA)

Study: Alpha Lipoic Acid in Geographic Atrophy ClinicalTrials.gov Identifier: NCT02613572 ALA: Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic … Continue reading

TG-MV-005

Status: Completed ClinicalTrials.gov Identifier: NCT00913744 TG-MV-005: Ocriplasmin injection in patients with wet AMD/focal vitreomacular adhesion. Condition:  Exudative Age-Related Macular Degeneration Focal Vitreomacular Adhesion Study Type: Interventional Duration: 3 years & 2 months Eligibility: Ages: 50 years and older Sexes: All Accepts Healthy Volunteers: No For … Continue reading

VGFT-OD-0706

Status: Completed ClinicalTrials.gov Identifier: NCT00789477 VGFT-OD-0706: Phase 2 study of intravitreal injections of Aflibercept in patients with Diabetic Macular Edema. Condition: Diabetic Macular Edema Study Type: Interventional Duration: 21 months Eligibility: Ages: 18 years and older Sexes: All Accepts Healthy Volunteers: No For … Continue reading

Quark QRK202

Status: Completed ClinicalTrials.gov Identifier: NCT01445899 Quark QRK202: 2 part study Part 1: Determines maximum tolerated dose of PF-04523655 Part 2: Study of PF-04523655 used alone and in combination with ranibizumab versus ranibizumab alone in patients with Diabetic Macular Edema. Condition(s): Choroidal Neovascularization Diabetic … Continue reading